Lupus erythematosus - Lupus Eritematosus
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
Jidher bħala eritema kemmxejn vjola.
Ir-raxx tal-farfett li tipikament jidher fuq il-wiċċ.
References
L-identifikazzjoni u l-klassifikazzjoni ta' cutaneous lupus erythematosus (CLE) toħloq sfidi dijanjostiċi, billi tiddistingwiha minn systemic lupus erythematosus bl-involviment tal-ġilda. Studji reċenti jitfgħu dawl fuq fatturi ġenetiċi, ambjentali u immunoloġiċi sottostanti CLE. L-induzzjoni tad-droga speċifikament ħarġet bħala waħda mill-aktar kawżi importanti għas-CLE. It-trattament jinvolvi terapiji topiċi u sistemiċi, inklużi bijoloġiċi promettenti (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , b'effikaċja murija fi provi kliniċi.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) tkopri diversi kwistjonijiet tal-ġilda, li wħud minnhom jistgħu jorbtu ma' problemi usa' tas-saħħa. Huwa kategorizzat f'tipi differenti, bħal acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE jinkludi discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus huwa grupp ta’ mard awtoimmuni li jista’ jaffettwa partijiet differenti tal-ġisem. Xi tipi, bħal systemic lupus erythematosus (SLE) , għandhom impatt fuq organi multipli, filwaqt li oħrajn, bħal cutaneous lupus erythematosus (CLE) , jaffettwaw prinċipalment il-ġilda. Aħna nikkategorizzaw tipi differenti ta 'CLE ibbażati fuq taħlita ta' sinjali kliniċi, eżami tat-tessuti, u testijiet tad-demm, iżda hemm ħafna varjazzjoni bejn l-individwi. Il-problemi tal-ġilda spiss jiżviluppaw minħabba fatturi bħall-espożizzjoni għad-dawl tax-xemx, it-tipjip, jew ċerti mediċini.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Il-kawża ta' lupus eritematosus (lupus erythematosus) mhix ċara. Fost tewmin identiċi, jekk wieħed ikun affettwat hemm ċans ta’ 24% li l-ieħor ikun ukoll. Ormoni sesswali femminili, dawl tax-xemx, tipjip, defiċjenza ta 'vitamina D, u ċerti infezzjonijiet huma wkoll maħsuba li jżidu r-riskju.
It-trattamenti jistgħu jinkludu NSAIDs, kortikosterojdi, immunosoppressanti, hydroxychloroquine, u methotrexate. Għalkemm il-kortikosterojdi huma effettivi, l-użu fit-tul jirriżulta f'effetti sekondarji.